RxDoctor Payments Data

Craig Vogel, DO

Cardiovascular Disease · Jupiter, FLNPI 1144298829

Payments from drug & device makers

$17,316in general payments, 2019–2025

Across 54 payments — averaging $320.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$13K
  • Boehringer Ingelheim$3K
  • Esperion Therapeutics, Inc.$745
  • Novartis$245
  • Astellas Pharma US Inc$198
  • E.r. Squibb & Sons, L.L.C.$184
  • plus $305 from 8 others

What the payments were for

  • Food & beverage$73579%
  • Education$19821%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$17,316 in reported general payments places this provider in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$668,629
Medicare patients
1,898
Services billed
7,851

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban850$1,040,947
XareltoRivaroxaban217$278,099
EntrestoSacubitril/Valsartan149$194,323
Repatha SureclickEvolocumab59$60,754
MultaqDronedarone Hcl30$60,608
Metoprolol Succinate1,006$13,435
JardianceEmpagliflozin11$13,182
Praluent PenAlirocumab17$12,064
Rosuvastatin Calcium923$12,063
Repatha SyringeEvolocumab18$11,305
Ranolazine ErRanolazine55$10,972
VascepaIcosapent Ethyl16$9,663
LivaloPitavastatin Calcium12$6,045
Atorvastatin Calcium599$5,737
BrilintaTicagrelor12$5,389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$16$1,040,947850 claims
Johnson & JohnsonXarelto$37$278,099217 claims
NovartisEntresto$245$194,323149 claims
Boehringer IngelheimJardiance$2,625$13,18211 claims
AstraZenecaBrilinta$25$5,38912 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Jupiter

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →